CompletedNo phase
Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 18 people enrolled
- Started
- 19 Feb 2026
- Ended
- 6 Aug 2026
- Type of study
- Interventional
- Treatments tested
- Auto-captioning Glasses
- Record updated
- 25 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Diagnosis of NF2-SWN by 2022 revised criteria
- Age 18 years or older at time of consent
- Willing and able to sign informed consent
- Access to a mobile phone with current operating software (i.e., iOS 16+ or Android 12+) and an internet connection
- Does not require prescription glasses to communicate others (e.g. may use reading glasses or similar)
- Resident of the U.S
- English-speaking
Who cannot take part
- Current use of auto-captioning glasses
Where in United States
- Massachusetts General HospitalBoston, United StatesNo longer taking part
About the trial
What the trial wants to find out
The goal of this clinical trial is to investigate the usability of auto-captioning glasses for adults diagnosed with NF2-related schwannomatosis and loss of hearing. The primary objective of the study is to determine the feasibility and acceptability of auto-captioning glasses in this population.
Read full original descriptionShow less
Participants will be asked to:
* Use the glasses at their discretion for 12 weeks * Report their feedback at 3 and 12 week timepoints via online surveys and remote qualitative interviews
The group in the trial
- Adults with NF2-SWN and Hearing LossTreatment being tested
Adults with a clinical diagnosis of NF2-SWN and self reported hearing loss will use the auto-captioning glasses for 12 weeks
Treatment: Auto-captioning Glasses
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 25 August 2026